Latest News and Press Releases

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s...

Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive...

Agomab announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA1 Phase 2a clinical trial for ontunisertib (AGMB-129)

Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.This report...

Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The "Capsule Endoscopy System Market Outlook 2025-2034: Market Share, and Growth Analysis" report has been added to ResearchAndMarkets.com's offering. ...

Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Tremfya Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's...

Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a...

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous...

Chicago, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The global organoids and spheroids market was valued at US$ 1,072.58 million in 2024 and is expected to reach US$ 6,613.97 million by 2033, growing at a...